Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Cash from Financing Activities data on record, last reported at $209.0 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed N/A year-over-year to $209.0 million; the TTM value through Dec 2025 reached $401.0 million, changed N/A, while the annual FY2025 figure was $488.0 million, 76.17% up from the prior year.
  • Cash from Financing Activities reached $209.0 million in Q4 2025 per RCUS's latest filing, up from $142.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $229.0 million in Q1 2024 and bottomed at $1.0 million in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $54.9 million, with a median of $11.0 million recorded in 2022.
  • The widest YoY moves for Cash from Financing Activities: up 36313.11% in 2021, down 99.32% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at $11.3 million in 2021, then dropped by 2.92% to $11.0 million in 2022, then plummeted by 72.73% to $3.0 million in 2023, then surged by 1500.0% to $48.0 million in 2024, then skyrocketed by 335.42% to $209.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $209.0 million in Q4 2025, $142.0 million in Q1 2025, and $48.0 million in Q3 2024.